Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study

被引：1

作者：

Pils, Marlene ^{[1
,2
]}

Dybala, Alexandra ^{[3
]}

Schaffrath, Anja ^{[1
]}

Rehn, Fabian ^{[1
,2
]}

Kutzsche, Janine ^{[1
]}

Bloemeke, Lara ^{[1
]}

Tusche, Markus ^{[1
]}

Oezduezenciler, Pelin ^{[1
]}

Bujnicki, Tuyen ^{[1
]}

Kraemer-Schulien, Victoria ^{[1
]}

Gramespacher, Hannes ^{[4
]}

Schmieschek, Maximilian H. T. ^{[4
]}

Barbe, Michael T. ^{[4
]}

Onur, Oezguer A. ^{[4
,5
]}

Fink, Gereon R. ^{[4
,5
]}

Tamguney, Gultekin ^{[1
,3
]}

Bannach, Oliver ^{[1
,2
]}

Willbold, Dieter ^{[1
,2
,3
]}

机构：

[1] Forschungszentrum Julich, Inst Biol Informat Proc, Struct Biochem IBI 7, D-52428 Julich, Germany

[2] attyloid GmbH, D-40225 Dusseldorf, Germany

[3] Heinrich Heine Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany

[4] Univ Cologne, Univ Hosp Cologne, Fac Med, Dept Neurol, D-50937 Cologne, Germany

[5] Res Ctr Julich, Inst Neurosci & Med INM 3, Cognit Neurosci, D-52428 Julich, Germany

来源：

ALZHEIMERS RESEARCH & THERAPY | 2024年 / 16卷 / 01期

关键词：

Amyloidosis; A beta oligomer quantitation; sFIDA; Brain-gut-microbiota axis; Leaky gut; Fecal/stool samples; Clearance; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; GUT-MICROBIOTA; DIAGNOSIS; BRAIN;

D O I：

10.1186/s13195-024-01597-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

BackgroundMisfolding and aggregation of amyloid beta (A beta), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer's disease (AD) onset and progression. In this study, we hypothesized the clearance of A beta aggregates from the brain and body into the gut.MethodsTo investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the A beta aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).ResultsA beta aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).ConclusionThus, fecal A beta aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant A beta aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.

引用

页数：15

共 50 条

[31] Phonetic compliance: a proof-of-concept study
Delvaux, Veronique
Huet, Kathy
Piccaluga, Myriam
Harmegnies, Bernard
FRONTIERS IN PSYCHOLOGY, 2014, 5
[32] Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease
Peter Lockwood
Wayne Ewy
David Hermann
Nick Holford
Pharmaceutical Research, 2006, 23
[33] A PROOF-OF-CONCEPT STUDY OF A MAGNETORHEOLOGICAL MICROPUMP
Cesmeci, Sevki
Hassan, Rubayet
Thompson, Mark
PROCEEDINGS OF ASME 2022 INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION, IMECE2022, VOL 2B, 2022,
[34] Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study
Nirogi, Ramakrishna
Ieni, John
Goyal, Vinod Kumar
Ravula, Jyothsna
Jetta, Satish
Shinde, Anil
Jayarajan, Pradeep
Benade, Vijay
Palacharla, Veera Raghava Chowdary
Dogiparti, Dhanunjay Kumar
Jasti, Venkat
Atri, Alireza
Cummings, Jeffrey
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
[35] Inhaled insulin: A proof-of-concept study
Cefalu, WT
ANNALS OF INTERNAL MEDICINE, 2001, 134 (09) : 795 - 795
[36] Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer's Disease Rat Model: A Proof-of-Concept Study
de Paula Faria, Daniele
Estessi de Souza, Larissa
Duran, Fabio Luis de Souza
Buchpiguel, Carlos Alberto
Britto, Luiz Roberto
Crippa, Jose Alexandre de Souza
Busatto Filho, Geraldo
Real, Caroline Cristiano
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
[37] Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
Lockwood, Peter
Ewy, Wayne
Hermann, David
Holford, Nick
PHARMACEUTICAL RESEARCH, 2006, 23 (09) : 2050 - 2059
[38] Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study
Park, So Hee
Baik, Kyoungwon
Jeon, Seun
Chang, Won Seok
Ye, Byoung Seok
Chang, Jin Woo
TRANSLATIONAL NEURODEGENERATION, 2021, 10 (01)
[39] InfiniCortex - From proof-of-concept to production
Noaje G.
Davis A.
Low J.
Seng L.
Lian T.G.
Orłowski L.P.
Chien D.
Sing-Wu L.
Wee T.T.
Poppe Y.
Kim Kenneth B.H.
Howard A.
Southwell D.
Gunthorpe J.
Michalewicz M.T.
Supercomputing Frontiers and Innovations, 2017, 4 (02) : 87 - 102
[40] Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
McDade, Eric
Cummings, Jeffrey L.
Dhadda, Shobha
Swanson, Chad J.
Reyderman, Larisa
Kanekiyo, Michio
Koyama, Akihiko
Irizarry, Michael
Kramer, Lynn D.
Bateman, Randall J.
ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)

← 1 2 3 4 5 →